A pilot study of the combination of lenalidomide (Revlimid) with two different dose levels of short term administration of recombinant human stem cell factor (rhSCF; ancestim) for myelodysplasia.

Trial Profile

A pilot study of the combination of lenalidomide (Revlimid) with two different dose levels of short term administration of recombinant human stem cell factor (rhSCF; ancestim) for myelodysplasia.

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 09 Jan 2013

At a glance

  • Drugs Lenalidomide (Primary) ; Ancestim
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 09 Jan 2013 Planned end date changed from 1 May 2012 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 11 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Aug 2011 Planned end date changed from 1 Feb 2009 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top